---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-126190"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:50:57.759366+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aptevo FY2025 net loss $26M, cash $21.6M; mipletamig 86% CBR in AML; CEO transition

## Summary
- Mipletamig triplet in 28 frontline AML patients: 86% CBR, 79% CR/CRi, no CRS observed.
- Expanded CD3 pipeline with three new candidates including first trispecific assets.
- Established $60M equity line with Yorkville; supports operations potentially into 2029.
- Cash $21.6M at Dec 31, 2025 (up from $8.7M); net loss $26.0M vs $24.1M in 2024.
- CEO Marvin White becomes Executive Chair; Jeff Lamothe named President and CEO.

## SEC filing metadata
- accession: 0001193125-26-126190
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000119312526126190/0001193125-26-126190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000119312526126190/apvo-20260326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-126190
- JSON: https://secwatch.observer/filing/0001193125-26-126190.json
- Plain text: https://secwatch.observer/filing/0001193125-26-126190.txt

## Key facts
- Earnings Releases
  Aptevo Therapeutics Inc. reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: On March 26, 2026, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671584/000119312526126190/0001193125-26-126190-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.